Brief: Jacobio Pharmaceuticals Says It Received IND Approval Of Drug From CDE Of PRC
06/12/2021 01:47
Dec 6 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* RECEIVED IND APPROVAL OF COMBINATION THERAPY OF KRAS G12C
INHIBITOR JAB-21822 AND CETUXIMAB INJECTION FROM CDE OF PRC
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan